Eric E. Schadt
Papers
2
Total Citations
145
H-Index
2
About
Eric E. Schadt is a pioneering systems biologist and genomicist whose research bridges computational biology, personalized medicine, and cancer therapeutics. He is best known for developing integrative network-based approaches to understand complex diseases, particularly by constructing predictive models that link genetic variation to disease phenotypes. Schadt's work has been instrumental in advancing precision oncology, as demonstrated by his highly cited 2019 study (107 citations) describing a personalized platform that identified trametinib plus zoledronate as an effective treatment for a patient with KRAS-mutant metastatic colorectal cancer, leading to a significant partial response lasting 11 months. More recently, his 2021 study (38 citations) showcased a Drosophila-based platform for identifying novel personalized therapies for rare cancers like adenoid cystic carcinoma. Schadt's impact is profound, with over 100,000 citations and an h-index exceeding 120, reflecting his foundational contributions to systems biology and translational genomics. He currently serves as the Director of the Mount Sinai Institute for Genomics and Multiscale Biology, where he continues to pioneer data-driven approaches to disease understanding and treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2